Alchemab Therapeutics is a healthcare company that is harnessing the power of naturally protective antibodies to develop novel products for patients with hard-to-treat diseases.
Founded in 2019 with a seed round led by SV Health Investors, a British Patient Capital fund manager, Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets, therapeutics and patient stratification tools through analysis of patient antibodies. The platform looks at entire antibody repertoires of individuals from well-defined groups who show unexpected resistance to disease despite genetic disposition or other risk factors predicative of a poor prognosis. Using the insights gained, Alchemab can identify naturally protective antibodies with therapeutic potential.
Alchemab’s approach was developed with support from scientific founders at Oxford University, Johns Hopkins University and Mount Sinai Hospital. It is amongst the first commercial group to access Illumina’s Cambridge, UK Accelerator.
In 2021, Alchemab raised a £60m Series A round from a host of investors, including a returning SV Health Investors and another of our fund managers, the Dementia Discovery Fund. The investment is being used to advance its unique target-agnostic drug discovery platform, as well as enable it to further advance its discovery programmes to clinic. It currently has a library of over 1,500 patient samples accessed through highly valued collaborations with academics, biobanks and industry partners.